Data Foundry

Drug recalls 2026

Levoxyl — Class II drug recall D-0052-2027

Ongoing recall by Pfizer, reported 2026-10-28, distributed nationwide. Subpotent Drug: confirmed out-of-specification (OOS) assay during stability testing.

Recall numberD-0052-2027
Product typeDrug
ClassificationClass II
StatusOngoing
Voluntary or mandatedVoluntary
Recalling firmPfizer, Manhattan, NY, United States
Recall initiated2026-09-29
Classified2026-10-16
Reported by FDA2026-10-28
DistributedNationwide (US)
Reason classespotency, specification failure
NDC60793-0850, 60793-0850-01, 60793-0850-10, 60793-0851, 60793-0851-01, 60793-0851-10, 60793-0852, 60793-0852-01, 60793-0852-10, 60793-0853, 60793-0853-01, 60793-0853-10, 60793-0854, 60793-0854-01, 60793-0854-10, 60793-0855, 60793-0855-01, 60793-0855-10, 60793-0856, 60793-0856-01, 60793-0856-10, 60793-0857, 60793-0857-01, 60793-0857-10, 60793-0858 and 8 more
Lot numbers24W06
Expiration dates2026-11-30

Product

Levoxyl (levothyroxine sodium tablets, USP), tablets, 175 mcg, 100 tablet bottle, Rx only, Distributed by Pfizer Inc., New York, NY 10017, Made in Austria. NDC 60793-859-01.

Reason for recall

Subpotent Drug: confirmed out-of-specification (OOS) assay during stability testing.

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0052-2027. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-11-03. Not affiliated with or endorsed by FDA. Not medical or legal advice.